EWA
HUMA icon

EverSource Wealth Advisors’s Humacyte HUMA Stock Holding History

EverSource Wealth Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98K Buy
5,098
+1,065
+26% +$987 ﹤0.01% 3401
2026
Q1 		$2.45K Buy
+4,033
New +$4.19K ﹤0.01% 3574
2025
Q4 		– Sell
-528
Closed -$919 – 4339
2025
Q3 		$919 Sell
528
-478
-48% -$936 ﹤0.01% 3787
2025
Q2 		$2.1K Buy
1,006
+956
+1,912% +$1.84K ﹤0.01% 3496
2025
Q1 		$85 Buy
50
+47
+1,567% +$176 ﹤0.01% 3849
2024
Q4 		$15 Buy
+3
New +$15 ﹤0.01% 3721

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EverSource Wealth Advisors's HUMA Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Humacyte (HUMA) stake by 26% in Q2 2026, buying an estimated $987 and bringing the position to 5,098 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #3401.

EverSource Wealth Advisors first reported a position in HUMA in Q4 2024 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • EverSource Wealth Advisors held 5,098 shares of Humacyte worth $3.98K as of Q2 2026.
  • EverSource Wealth Advisors bought 1,065 Humacyte shares in Q2 2026, an estimated $987.
  • Humacyte made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3401 holding.
  • EverSource Wealth Advisors first reported a position in Humacyte in Q4 2024 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.